Navigation Links
Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
Date:10/27/2010

MENLO PARK, Calif.,  Oct. 27 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that H. Mario Geysen, Ph.D., has joined SRI International's Center for Advanced Drug Research (CADRE) in Shenandoah Valley, Virginia. In his new role, Dr. Geysen will expand SRI's research capabilities into diseases such as diabetes and osteoporosis and will establish programs to develop novel molecules that control hormonal regulation in metabolic diseases.

Dr. Geysen is a pioneer in the field of combinatorial chemistry, which is often described as the intersection of chemistry, robotics, instrumentation, computer science, and engineering. It is recognized that combinatorial chemistry has dramatically altered and accelerated the pace of pharmaceutical discovery and development. Several new therapies are currently under development that will help provide needed medicines to patients.

"Mario Geysen is a distinguished scientist.  His invaluable contributions towards the development of innovative technologies have led to novel therapies," said Krishna Kodukula, Ph.D., CADRE executive director. Walter H. Moos, Ph.D., vice president of SRI Biosciences, added, "Having had the utmost respect for Mario ever since we first met in the late 1980s, I am very pleased to welcome him to SRI, and look forward to the leadership he will provide to our researchers addressing complex drug discovery challenges."

Prior to joining SRI, Dr. Geysen was the Alfred Burger Professor of Chemistry at the University of Virginia (now Emeritus). Previous to that, he was a Distinguished Scientist at GlaxoSmithKline. Dr. Geysen's career includes experience in government, industry, and academia. He has founded several successful biotechnology firms, including Mimotopes, and has developed many innovative technologies for pharmaceutical drug discovery.

Dr. Geysen has received numerous awards in the U.S. and internationally and has more than 125 publications and patents. He holds advanced degrees in chemistry and microbiology from the University of Melbourne, Australia, and in chemical engineering from University College, London (U.K.).

About SRI's Center for Advanced Drug Research (CADRE)

SRI established the Center for Advanced Drug Research (CADRE) to improve the productivity of the pharmaceutical industry, help our nation respond to biothreats, and develop life-saving treatments for rare and neglected diseases. CADRE's mission is to create new therapeutics, diagnostics, and vaccines for infectious and other diseases and for biodefense. CADRE combines and partners with SRI's well-established expertise in drug discovery, computational biology, and preclinical development with a new proteomics laboratory to develop these solutions.

About SRI's Biosciences Division

SRI's Biosciences division carries out basic research, drug discovery, and drug development, and provides contract (CRO) services. SRI has all of the resources necessary to take R&D from "Idea to IND"®—from initial discovery to the start of human clinical trials—and specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI's product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and commercial clients and partners advance many drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International is one of the world's leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years. Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more. The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations. SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies. In 2009, SRI's consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $470 million. Sarnoff Corporation, a leader in vision, video, and semiconductor innovations, will be fully integrated into SRI effective January 1, 2011.


'/>"/>
SOURCE SRI International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stuart Parkin first distinguished professor at Eindhoven University of Technology
2. Clemson scientists put a (nano) spring in their step
3. City of Hope Helps KGI Launch New Management Training Program for Scientists
4. University of Pennsylvania scientists move optical computing closer to reality
5. Scientists grow nanonets able to snare added energy transfer
6. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
7. Scientists peel away the mystery behind golds catalytic prowess
8. SACHEM Launches 2-D HPLC e-Learning Program : New e-Learning Program Teaches Scientists How to Better Analyze and Prove Product Purity Through Greater Sensitivity and Precision in Identification of Trace Components
9. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
10. Brewing better beer: Scientists determine the genomic origins of lager yeasts
11. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Fitzmaurice recently became double board-certified in surgery and surgery of the hand by ... Fitzmaurice is no stranger to going above and beyond in his pursuit of ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Food and Drug Administration (FDA) has granted the company’s orphan drug designation request ... second orphan drug designation granted by the FDA. , Spinocerebellar ataxia is ...
(Date:5/23/2016)... ... May 23, 2016 , ... The need for blood donations in South Texas and across the ... Texas Blood & Tissue Center, blood donations are on the decline. In fact, donations across ... down 21 percent in South Texas in the last four years alone. , There is ...
(Date:5/23/2016)... ... May 23, 2016 , ... RoviSys, a ... based in Aurora, Ohio, has broken ground on a new building in Holly ... Park area, this new location solidifies a commitment to business in the region. ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):